Hsbc Holdings PLC raised its stake in STERIS plc (NYSE:STE - Free Report) by 93.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 82,604 shares of the medical equipment provider's stock after purchasing an additional 39,894 shares during the period. Hsbc Holdings PLC owned 0.08% of STERIS worth $16,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also added to or reduced their stakes in the company. Franklin Resources Inc. raised its stake in shares of STERIS by 171.2% during the 3rd quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after acquiring an additional 529,308 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in STERIS by 30.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after purchasing an additional 2,583 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of STERIS during the third quarter worth $9,949,000. Merit Financial Group LLC purchased a new stake in shares of STERIS during the 4th quarter valued at $260,000. Finally, Blue Trust Inc. boosted its position in shares of STERIS by 19.9% in the 4th quarter. Blue Trust Inc. now owns 1,128 shares of the medical equipment provider's stock worth $232,000 after purchasing an additional 187 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
STE has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. JMP Securities reiterated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a research note on Thursday, April 10th. Piper Sandler upped their price target on shares of STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. Finally, Stephens reaffirmed an "overweight" rating and issued a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.
Get Our Latest Stock Report on STERIS
STERIS Stock Down 0.6 %
Shares of STE stock opened at $225.00 on Friday. STERIS plc has a twelve month low of $200.98 and a twelve month high of $248.24. The stock has a market cap of $22.11 billion, a P/E ratio of 47.77 and a beta of 0.87. The stock has a 50 day moving average of $222.89 and a 200 day moving average of $218.90. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.
STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. As a group, sell-side analysts expect that STERIS plc will post 9.08 EPS for the current year.
STERIS Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Shareholders of record on Thursday, February 20th were issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 1.01%. The ex-dividend date of this dividend was Thursday, February 20th. STERIS's payout ratio is currently 48.41%.
STERIS Company Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
